NASDAQ:NVLN - Novelion Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Novelion Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVLN

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Novelion Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for NVLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Novelion Therapeutics. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/14/2018Bloom BurtonDowngradeAccumulate ➝ HoldMedium
8/9/2018Royal Bank of CanadaLower Price TargetHold$6.00 ➝ $5.00Medium
5/14/2018Royal Bank of CanadaLower Price TargetSector Perform$7.00 ➝ $6.00High
3/16/2018Royal Bank of CanadaReiterated RatingHold$8.00 ➝ $7.00Low
11/10/2017Royal Bank of CanadaLower Price TargetSector Perform$9.00 ➝ $8.00N/A
10/3/2017Royal Bank of CanadaReiterated RatingHold$9.00Low
8/8/2017Royal Bank of CanadaSet Price TargetHold$10.00 ➝ $9.00High
(Data available from 7/5/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Novelion Therapeutics logo
Novelion Therapeutics Inc., a biopharmaceutical company, develops a portfolio of therapies for individuals living with rare diseases in the United States, Brazil, and internationally. The company's commercial products include lomitapide hard capsule for the treatment of homozygous familial hypercholesterolemia in adults under the JUXTAPID and LOJUXTA brands; and metreleptin, a recombinant analogue of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPT brand. Its orphan drug-designated product candidate is zuretinol acetate, an oral synthetic retinoid, which is in development for the treatment of inherited retinal disease caused by underlying mutations in retinal pigment epithelium protein 65 and lecithin: retinol acyltransferase genes. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.70
Low: $0.68
High: $0.70

52 Week Range

Now: N/A

Volume

26,947 shs

Average Volume

190,529 shs

Market Capitalization

$13.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Novelion Therapeutics?

The following equities research analysts have issued stock ratings on Novelion Therapeutics in the last twelve months:
View the latest analyst ratings for NVLN.

What is the current price target for Novelion Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Novelion Therapeutics in the last year.
View the latest price targets for NVLN.

What is the current consensus analyst rating for Novelion Therapeutics?

Novelion Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NVLN.

How do I contact Novelion Therapeutics' investor relations team?

Novelion Therapeutics' physical mailing address is 1800 - 510 WEST GEORGIA STREET, VANCOUVER A1, V6B 0M3. The biotechnology company's listed phone number is 617-500-7867 and its investor relations email address is [email protected] The official website for Novelion Therapeutics is www.novelion.com. Learn More about contacing Novelion Therapeutics investor relations.